TY - JOUR
T1 - New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor
AU - Feng, X.
AU - Pak, R. H.
AU - Kroger, L. A.
AU - Moran, J. K.
AU - DeNardo, D. G.
AU - Meares, C. F.
AU - DeNardo, G. L.
AU - DeNardo, S. J.
PY - 1998
Y1 - 1998
N2 - Monoclonal antibodies were raised against yttrium(III)-1, 4, 7, 10- tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (Y-DOTA) and copper(II)- 1, 4, 8, 11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (Cu- TETA). Four hybridomas with high Y-DOTA binding activity and one hybridoma with Cu-TETA activity were selected. MAbs were purified from mouse ascites by Protein A affinity chromatography and characterized. Affinity constants were determined by equilibrium dialysis and the highest affinity Y-DOTA MAb (K(aff) = 1.9 x 108 M-1) was further characterized by competitive ELISA. Gd-DOTA competed as well as Y-DOTA, whereas In-DOTA required 740x higher concentrations for 50% inhibition of this Y-DOTA MAb binding to human serum albumin-Y-DOTA-coated microtiter plates. These anti-metal chelate MAbs have potential use as vehicles for the pretargeted delivery of radiometal chelates to tumors.
AB - Monoclonal antibodies were raised against yttrium(III)-1, 4, 7, 10- tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (Y-DOTA) and copper(II)- 1, 4, 8, 11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (Cu- TETA). Four hybridomas with high Y-DOTA binding activity and one hybridoma with Cu-TETA activity were selected. MAbs were purified from mouse ascites by Protein A affinity chromatography and characterized. Affinity constants were determined by equilibrium dialysis and the highest affinity Y-DOTA MAb (K(aff) = 1.9 x 108 M-1) was further characterized by competitive ELISA. Gd-DOTA competed as well as Y-DOTA, whereas In-DOTA required 740x higher concentrations for 50% inhibition of this Y-DOTA MAb binding to human serum albumin-Y-DOTA-coated microtiter plates. These anti-metal chelate MAbs have potential use as vehicles for the pretargeted delivery of radiometal chelates to tumors.
UR - http://www.scopus.com/inward/record.url?scp=0031833527&partnerID=8YFLogxK
U2 - 10.1089/hyb.1998.17.125
DO - 10.1089/hyb.1998.17.125
M3 - Article
C2 - 9627052
AN - SCOPUS:0031833527
SN - 0272-457X
VL - 17
SP - 125
EP - 132
JO - Hybridoma
JF - Hybridoma
IS - 2
ER -